Interactome Biotherapeutics
June 17, 2025
Company Presentation
Platform for Therapeutics
We are revolutionizing drug delivery by harnessing proprietary progenitor cell nanotechnology to deliver medicines in a better way. We are currently in the midst of IND-enabling studies for IB001 for the treatment of neuropathic pain. In preclinical studies, IB001 has shown to enhance the neural immune system, increase axonal outgrowth, boost neural mitochondria, and induce a widespread anti-inflammatory signal. Interactome is advancing its Nanovate sEV Engineering Platform for delivery of nucleic acids (siRNA, miRNA, mRNA, gRNA), proteins/peptides, small-molecule, and aptamers. Unique G58 modification specifically enables high efficiency loading of specific cargoes on the exosome surface, while standard loading methods allow incorporation of other payloads like small molecules or aptamers. This versatility allows delivery of gene silencers, gene editors, mRNA vaccines, enzymes, or even hydrophobic drugs via surface conjugation and/or endogenous delivery.
.png)
Company HQ City:
Grand Rapids
Company HQ State:
MI
Company HQ Country:
United States
Year Founded:
2020
Lead Product in Development:
IB001
Nanovate Platform
CEO
Adam Koster
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
Closing Seed Round
What is your next catalyst (value inflection) update?
June 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}